guide biological repair processes, aiming to address degenerative diseases, neurological injuries, and musculoskeletal conditions. Amphix Bio advances multiple preclinical and early clinical candidate programs, including therapies targeting spinal cord injury and other neurological disorders, by engineering peptide assemblies to modulate cell behavior and tissue growth. Its pipeline includes treatments that have received regulatory designations in recognition of their potential to treat serious conditions and inform clinical development pathways. The company’s scientific approach is rooted in long-standing academic research, and it continues to refine its peptide technologies to support broader therapeutic applications that restore function lost to injury or disease. Amphix Bio operates with a focus on translating complex molecular science into therapeutic candidates and supporting the progression of its regenerative products toward human clinical evaluation.